Rafael Pharmaceuticals, Inc. ("Rafael" or the "Company"), a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration (FDA)
Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.15) per share. This is a 7.14 percent decrease over losses of $(0.14) per share from the same period last year. The company reported $1.00 million in sales
Toward the end of trading Friday, the Dow traded up 0.33% to 34,579.84 while the NASDAQ rose 0.40% to 13,791.88. The S&P also rose, gaining 0.29% to 4,212.91.